close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by GenSight Biologics

GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US
From GenSight Biologics
Via Business Wire
GenSight Biologics Reports Cash Position as of September 30, 2025
From GenSight Biologics
Via Business Wire
GenSight Biologics Reports Interim Financial Results for the First Half of 2025
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
From GenSight Biologics
Via Business Wire
GenSight Biologics Reports Cash Position as of June 30, 2025
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
From GenSight Biologics
Via Business Wire
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
From GenSight Biologics
Via Business Wire
GenSight Biologics Annual General Meeting on May 13, 2025
From GenSight Biologics
Via Business Wire
GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update
From GenSight Biologics
Via Business Wire
GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
From GenSight Biologics
Via Business Wire
GenSight Biologics Reports End-of-Year Cash Position and Provides Business Update
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024
From GenSight Biologics
Via Business Wire
GenSight Biologics Launches Newsletter for Retail Investors
From GenSight Biologics
Via Business Wire
GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings
From GenSight Biologics
Via Business Wire
GenSight Biologics Appoints William Monteith to its Board of Directors
From GenSight Biologics
Via Business Wire
GenSight Biologics: Annual General Meeting on May 29, 2024
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces its 2024 Financial Calendar
From GenSight Biologics
Via Business Wire
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy
From GenSight Biologics
Via Business Wire
GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®
From GenSight Biologics
Via Business Wire
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection
From GenSight Biologics
Via Business Wire
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
From GenSight Biologics
Via Business Wire
GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment
From GenSight Biologics
Via Business Wire
GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting
From GenSight Biologics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today